Тамоксифен-ассоциированный рак эндометрия: ключевые предикторы и мониторинг

1. Bray F., Ferlay J., Laversanne M., Brewster D.H., Gombe Mbalawa C., Kohler B. et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int. J. Cancer. 2015; 137(9): 2060-71. https://dx.doi.org/10.1002/ijc.29670
2. Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022. 252 с.
3. Davies C., Godwin J., Gray R., Clarke M., Cutter D. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793): 771-84. https://dx.doi.org/10.1016/S0140-6736(11)60993-8
4. Тюляндин С.А., Артамонова Е.В., Жигулев А.Н., Королева И.А., Пароконная А.А., Семиглазова Т.Ю., Стенина М.Б., Фролова М.А. Рак молочной железы. Malignant tumours. 2023; 13(3s2-1): 157-200.
5. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Рак молочной железы. 2021.
6. Gradishar W.J., Moran M.S., Abraham J., Aft R., Agnese D., Allison K.H. et al. Breast cancer, version 3.2022, NCCN Clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2022; 20(6): 691-722. https://dx.doi.org/10.6004/jnccn.2022.0030
7. Гусейнова Р.Г., Ордиянц И.М., Персидская А.А. Клинически значимые факторы риска развития гиперпластических процессов эндометрия у женщин в перименопаузальном возрасте. Акушерство и гинекология. 2021; 8: 32-8.
8. Bernstein L., Deapen D., Cerhan J.R., Schwartz S.M., Liff J., McGann-Maloney E. et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer Inst. 1999; 91(19): 1654-62. https://dx.doi.org/10.1093/jnci/91.19.1654
9. Ryu K.J., Kim M.S., Lee J.Y., Nam S., Jeong H.G., Kim T. et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw. Open. 2022; 5(11): e2243951. https://dx.doi.org/10.1001/jamanetworkopen.2022.43951
10. Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet. Gynecol. 2014; 123(6): 1394-7. https://dx.doi.org/10.1097/01.AOG.0000450757.18294.cf
11. Hoogendoorn W.E., Hollema H., van Boven H.H., Bergman E., de Leeuw-Mantel G., Platteel I. et al. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res. Treat. 2008; 112(1): 99-108. https://dx.doi.org/10.1007/s10549-007-9823-1.
12. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994; 86(7): 527-37. https://dx.doi.org/10.1093/jnci/86.7.527
13. Ngô C., Brugier C., Plancher C., de la Rochefordière A., Alran S., Féron J.G. et al. Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients. Eur. J. Surg. Oncol. 2014; 40(10): 1237-44. https://dx.doi.org/10.1016/j.ejso.2014.05.007
14. Choi S., Lee Y.J., Jeong J.H., Jung J., Lee J.W., Kim H.J. et al. Risk of endometrial cancer and frequencies of invasive endometrial procedures in young breast cancer survivors treated with tamoxifen: a nationwide study. Front. Oncol. 2021; 11: 636378. https://dx.doi.org/10.3389/fonc.2021.636378
15. Swerdlow A.J., Jones M.E. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J. Natl. Cancer Inst. 2005; 97(5): 375-84. https://dx.doi.org/10.1093/jnci/dji057
16. Chen J.Y., Kuo S.J., Liaw Y.P., Avital I., Stojadinovic A., Man Y.G. et al. Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study. J. Cancer. 2014; 5(2): 151-5. https://dx.doi.org/10.7150/jca.8412
17. Berlière M., Charles A., Galant C., Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet. Gynecol. 1998; 91(1): 40-4. https://dx.doi.org/10.1016/s0029-7844(97)00591-7
18. Hu R., Hilakivi-Clarke L., Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (review). Oncol. Lett. 2015; 9(4): 1495-501. https://dx.doi.org/10.3892/ol.2015.2962
19. López D.M.L., Fernández Y.G., Sánchez A.V., Alvarez M.I., Reynaldo M.I.L., Delgado R.C. Baseline hysteroscopic assessment of endometrium in asymptomatic postmenopausal women with estrogen receptor-positive breast cancer. Menopause. 2013; 20(1): 64-71. https://dx.doi.org/10.1097/gme.0b013e318259eaf3
20. Garuti G., Grossi F., Centinaio G., Sita G., Nalli G., Luerti M. Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007; 132(1): 101-6. https://dx.doi.org/10.1016/j.ejogrb.2006.04.001
21. Stern T., Peleg Hasson S., Saad A., Levanon K., Michaan N., Laskov I. et al. Concomitant diagnosis of endometrial and breast cancer - does the sequence matters? Gynecol. Oncol. Rep. 2021; 38: 100863. https://dx.doi.org/10.1016/j.gore.2021.100863
22. Matanes E., Volodarsky-Perel A., Eisenberg N., Rottenstreich M., Yasmeen A., Mitric C. et al. Endometrial cancer in germline BRCA mutation carriers: a systematic review and meta-analysis. J. Minim. Invasive Gynecol. 2021; 28(5): 947-56. https://dx.doi.org/10.1016/j.jmig.2020.11.023
23. Li Z., Wu Q., Song J., Zhang Y., Zhu S., Sun S. Risk of second primary female genital malignancies in women with breast cancer: a SEER analysis. Horm. Cancer. 2018; 9(3): 197-204. https://dx.doi.org/10.1007/s12672-018-0330-0
24. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive cancer centres’ ALERT group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet. 2000; 356(9233): 881-7. https://dx.doi.org/10.1016/s0140-6736(00)02677-5
25. Ghanavati M., Khorshidi Y., Shadnoush M., Akbari M.E., Ardehali S.H., Chavarri-Guerra Y. et al. Tamoxifen use and risk of endometrial cancer in breast cancer patients: a systematic review and dose-response meta-analysis. Cancer Rep. (Hoboken). 2023; 6(4): e1806. https://dx.doi.org/10.1002/cnr2.1806
26. Magriples U., Naftolin F., Schwartz P.E., Carcangiu M.L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 1993; 11(3): 485-90. https://dx.doi.org/10.1200/JCO.1993.11.3.485
27. Decensi A., Gandini S., Serrano D., Cazzaniga M., Pizzamiglio M., Maffini F. et al. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J. Clin. Oncol. 2007; 25(27): 4201-9. https://dx.doi.org/10.1200/JCO.2006.09.4318
28. Fleming C.A., Heneghan H.M., O’Brien D., McCartan D.P., McDermott E.W., Prichard R.S. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br. J. Surg. 2018; 105(9): 1098-106. https://dx.doi.org/10.1002/bjs.10899
29. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381(9869): 805-16. https://dx.doi.org/10.1016/S0140-6736(12)61963-1
30. Earl H., Gray R., Kerr D., Lee M. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom. Clin. Oncol. (R. Coll. Radiol.). 1997; 9(3): 141-3. https://dx.doi.org/10.1016/s0936-6555(97)80067-2
31. Rosell J., Nordenskjöld B., Bengtsson N.-O., Fornander T., Hatschek T., Lindman H. et al. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen. Acta Oncol. 2017; 56(4): 614-7. https://dx.doi.org/10.1080/0284186X.2016.1273547
32. Gielen S.C.J.P., Santegoets L.A.M., Hanifi-Moghaddam P., Burger C.W., Blok L.J. Signaling by estrogens and tamoxifen in the human endometrium. J. Steroid Biochem. Mol. Biol. 2008; 109(3-5): 219-23. https://dx.doi.org/10.1016/j.jsbmb.2008.03.021
33. Ольховская М.А., Сметник А.А. Селективные модуляторы эстрогеновых рецепторов. Акушерство и гинекология. 2011; 6: 31-5.
34. Kurt S., Ozmen S., Yavuz O., Ilgen O., Ulukus E.C. Endometrial pathologies in clinical follow-up of patients with hormone receptor-positive / negative breast cancer. J. Surg. Med. 2023; 7(12): 754-9. https://dx.doi.org/10.28982/josam.7583
35. Gielen S.C.J.P., Burger C.W., Kühne L.C.M., Hanifi-Moghaddam P., Blok L.J. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J. Soc. Gynecol. Investig. 2005; 12(7): e55-67. https://dx.doi.org/10.1016/j.jsgi.2005.08.003
36. Gorodeski G.I., Beery R., Lunenfeld B., Geier A. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium. Fertil. Steril. 1992; 57(2): 320-7. https://dx.doi.org/10.1016/s0015-0282(16)54838-9
37. Chu S.C., Hsieh C.J., Wang T.F., Hong M.K., Chu T.Y. Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: a population-based study in Taiwan. Tzu Chi Med. J. 2019; 32(2): 175-80. https://dx.doi.org/10.4103/tcmj.tcmj_17_19
38. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M. et al. Tamoxifen for prevention of breast cancer: report of the National surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst. 1998; 90(18): 1371-88. https://dx.doi.org/10.1093/jnci/90.18.1371
39. Shum M.J. Risk factors for endometrial pathology in women with breast cancer and tamoxifen treatment. Hong Kong J. Gynaecol. Obstet. Midwifery. 2022; 22(2): 107-13. https://dx.doi.org/10.12809/hkjgom.22.2.02
40. Cheng W.F., Lin H.H., Torng P.L., Huang S.C. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol. Oncol. 1997; 66(2): 233-7. https://dx.doi.org/10.1006/gyno.1997.4739
41. Мамиконян И.О., Саркисов С.Э., Бойко М.А., Гюрджян С.А., Саттаров Ш.Н. Сравнительная оценка методов диагностики состояния эндометрия у пациенток в постменопаузе с раком молочной железы на фоне приема тамоксифена. Акушерство и гинекология. 2013; 10: 59-62.
42. Chiofalo B., Mazzon I., Di Angelo Antonio S., Amadore D., Vizza E., Laganà A.S. et al. Hysteroscopic evaluation of endometrial changes in breast cancer women with or without hormone therapies: results from a large multicenter cohort study. J. Minim. Invasive Gynecol. 2020; 27(4): 832-9. https://dx.doi.org/10.1016/j.jmig.2019.08.007
43. Li W., Chen Q., Xie Y., Hu J., Yang S., Lin M. Prevalence and degree of insulin resistance in Chinese Han women with PCOS: Results from euglycemic-hyperinsulinemic clamps. Clin. Endocrinol. (Oxf). 2019; 90(1): 138-44. https://dx.doi.org/10.1111/cen.13860

Поступила 19.01.2026

Принята в печать 25.03.2026